Stevanato Group SpA (STVN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $4.32B
Last updated: Nov 17, 2026 at 11:05 AM ET
Stevanato Group SpA (STVN) P/E Ratio & Valuation Multiples
Stevanato Group SpA (STVN) trades at 19.9x trailing earnings and 3.0x sales. Its P/S of 3.0x is below its 5-year median of 4.8x. Its forward P/E is 24.7x. The median P/E across 11 similar companies is 26.6x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 19.4% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 19.9x |
| Forward P/E | 24.7x |
| Price to sales | 3.0x |
| Price to book | 2.4x |
| EV/EBITDA | 13.1x |
| PEG | 2.0 |
| FCF yield | -0.0% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.0x | 4.8x | N/A |
| P/B | 2.4x | 4.3x | N/A |
Valuation History
Over the 5 year ends shown, its P/S ranged from 4.0x in 2025 to 6.4x in 2021. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $20.12 | 4.0x | 3.1x |
| 2024 | $21.79 | 5.0x | 4.1x |
| 2023 | $27.29 | 6.2x | 5.8x |
| 2022 | $17.97 | 4.6x | 4.5x |
| 2021 | $22.45 | 6.4x | 6.2x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About STVN
What is STVN's forward P/E ratio?
Stevanato Group SpA has a forward P/E ratio of 24.7x.
Is STVN stock overvalued?
GNG's valuation label for STVN is Undervalued. Its P/E of 19.9x compares with a median of 26.6x across 11 similar companies.
What is STVN's price to sales ratio?
Stevanato Group SpA has a price to sales ratio of 3.0x.
What is STVN's PEG ratio?
Stevanato Group SpA has a PEG ratio of 2.0.
STVN pages: Overview, Financials, Valuation, Competitors